ESMO Annual Congress Coverage
The European Society for Medical Oncology annual congress for 2023 takes place in Madrid, Spain from 20-24 October. This page is your one-stop shop for all of Scrip's conference coverage, including preview and post-meeting analysis. You can also find archive content from previous meetings here.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.
Pipeline Watch: Four Approvals And 21 Phase III Trial Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Five Clinical Trial Hits Of 2023
The biopharma industry’s fate lies largely in its R&D successes and failures. Here, Scrip looks at five clinical trial successes that will shape their sponsors’ futures and got readers clicking in 2023.
BMS Bets $8.4bn On Biokin’s Bispecific ADC
In a record licensing deal involving a single biopharma asset from China, Biokin and its US subsidiary SystImmune will receive up to $8.4bn from BMS, including $800m upfront, for a bispecific ADC with broad oncology potential.
Pipeline Watch: 10 Approvals And 22 Phase III Trial Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Olema Boosts Its Partnering Position With SERD Combo Data
Scrip caught up with Olema CEO Sean Bohen ahead of a crucial combination data readout due this month for its novel SERD, palazestrant, which it hopes will put the drug on the path to a $10bn-plus breast cancer market.
SpringWorks’ Ogsiveo Is First-Ever US FDA-Approved Drug For Desmoid Tumors
SpringWorks’ gamma secretase inhibitor will be available soon for adults at any stage of treatment for desmoid tumors with a list price of $29,000 for a 30-day supply.
AstraZeneca Wins The AKT Race With Truqap
The UK big pharma gets a first-in-class approval in breast cancer, but a challenger is emerging.
Merck KGaA Sticks With Structure, Eyes Smaller Healthcare Deals
There may be a trend towards spinning off business units but Merck continues to sees its three-pillar structure as providing the best protection from downturns in any individual segment.
Finance Watch: Lexeo Launches 20th US Biopharma IPO In 2023
Public Company Edition: Lexeo raised $100m to advance its genetic medicines. Also, Blue Owl Capital acquired funds managed by Cowen Healthcare Investments, gaining about $1bn in life science assets, BMS priced $4.5bn in notes to fund its Mirati purchase and Viridian raised $185m in a private placement.
A Gloomy Outlook On Macro Trends From Industry CEOs
Pfizer CEO Albert Bourla, Eli Lilly CEO David Ricks and Seagen CEO David Epstein discussed pressing issues facing the pharmaceutical industry at the recent Galien Forum.
Pipeline Watch: Updates from ESMO and CTAD Dominate
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Chinese Language Podcast: ESMO China Data, Annual CDE Report, Shanghai Biopharma Week
Topics in this latest Chinese-language podcast include the China Center for Drug Evaluation's annual IND and NDA report, highlights of Chinese companies' data readouts at ESMO, and policy signals from the International Biopharma Industry Week Shanghai.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: did Pfizer miss out on Roivant/Roche deal?; Padcev/Keytruda combo impresses in bladder cancer at ESMO; biggest upfront ever in Daiichi/Merck deal; Rybrevant at ESMO; and subcu Leqembi could open up access.
ESMO 23: Analysts Keep Faith In Revolution’s Multi-RAS Drug Despite Investor Fright
Revolution Medicines is aiming to go beyond Amgen and Mirati’s first-generation drugs with a multi-RAS targeting therapy - and despite a market sell-off after ESMO, analysts think the company think it is still on track.
Merck Points To Antibody-Drug Conjugate Potential During Another Growth Quarter
Keytruda brought in its usual stacks of cash, but Merck’s Q3 earnings call focused largely on a recent alliance with Daiichi Sankyo and the pharma’s growing emphasis on cancer ADCs.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.